Trial Profile
An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- 22 Oct 2014 New trial record